Replies to post #185152 on Biotech Values

[marthambles]

FGEN does not generate a lot of buzz

Puzzling given the extraordinary potential of Roxadustat if safety pans out. The stock has done nicely since its IPO, however. As Peter said, this should be a core biotech holding, imo.